Jazz Pharmaceuticals

This early-phase study tests an oral drug called ONC206 in 102 adults with brain tumors that have come back or are rare. The main goal is to find the safest dose and understand side effects. Participants take the drug by mouth on a weekly schedule, and researchers monitor for any…

This study tests whether adding zanidatamab to standard chemotherapy can completely eliminate cancer in the breast and armpit before surgery in people with early-stage HER2-positive breast cancer. About 125 participants with stage II or III disease will receive the combination an…

This study tests whether adding the drug zanidatamab to standard chemotherapy (with or without an immunotherapy) helps people with advanced HER2-positive bile duct cancer live longer without their cancer growing. About 286 adults whose cancer cannot be removed by surgery will be …

This early-stage study tests a new drug called JZP898, alone or with another drug (pembrolizumab), in adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the right dose, and see if the drug shrinks tumors. Abo…

This study tests a drug called zanidatamab in about 200 adults with advanced HER2-positive cancers (like breast, stomach, lung, or ovarian cancer) that have worsened after at least one prior treatment. The goal is to see if the drug can shrink tumors and how long that effect last…

This study tests a new drug called JZP815 in people with advanced or spreading solid tumors that have specific genetic changes in the MAPK pathway. The main goals are to find a safe dose and see if the drug can shrink tumors. About 332 adults who have tried all other standard tre…

This study tests a drug called lurbinectedin in children and young adults (ages 2 to 30) with solid tumors, especially Ewing sarcoma that has returned or not responded to prior treatment. The first part finds the safest dose; the second part checks if the drug shrinks tumors. Abo…

This study tests an experimental drug called ONC206 in 90 adults with advanced pheochromocytoma or paraganglioma (rare tumors of the adrenal glands or nerve tissue). The goal is to see if the drug can shrink tumors or stop them from growing. Participants must have tumors that can…

This study tests whether the drug ONC201 can help people with a rare and aggressive brain tumor called H3 K27M-mutant glioma live longer. Participants must have completed standard radiation therapy. The trial is double-blind, meaning neither patients nor doctors know who gets the…

This study tests whether a new drug called zanidatamab, combined with chemotherapy, works better than the current standard treatment (trastuzumab plus chemo) for people with advanced HER2-positive breast cancer that has worsened after or cannot tolerate a prior treatment. About 5…

This study follows about 100 people with Lennox-Gastaut, Dravet, or tuberous sclerosis complex who are prescribed Epidyolex (a CBD liquid) alongside their usual seizure medicines. Researchers will track how long people stay on the treatment and how many seizure-free days they hav…

This study tests a cannabidiol (CBD) oral solution in 100 people aged 12 to 75 who have focal-onset seizures. The goal is to see if the treatment can safely reduce seizure frequency. Participants take the liquid CBD daily, and researchers track changes in seizure counts over time…

This study follows 50 pregnant women who have taken the seizure medication Epidiolex (cannabidiol) to see if it affects pregnancy outcomes or the health of their baby up to 12 months old. Researchers will track complications like birth defects, miscarriage, and preterm delivery. …

This early-stage study tests the safety of a new drug, JZP047, in healthy adults aged 18 to 55. Participants receive either a single dose of the drug or a placebo, and researchers monitor side effects and how the drug moves through the body. A separate part looks at whether food …